Table 1.
Comparison of clinical characteristics and outcomes of patients treated with two different doses of TMP/SMX
| Clinical parameter | Result for TMP/SMX twice-daily dose of: |
Odds ratio | 95% confidence interval | P value | |
|---|---|---|---|---|---|
| 160/800 mg (n = 170) | 320/1,600 mg (n = 121) | ||||
| Median (range) age (yr) | 38 (24-52) | 40 (28-52) | 0.433 | ||
| No. (%) female gender | 87 (51.2) | 52 (43.0) | 0.72 | 0.45–1.15 | 0.19 |
| Median (range) body wt (kg) | 77 (44.5-156) | 86 (42-141) | 0.553 | ||
| Median (range) body mass index | 28 (16.8-54) | 30 (18-58.8) | 0.454 | ||
| No. (%) of patients with: | |||||
| Diabetes mellitus | 32 (18.8) | 23 (19.0) | 1.01 | 0.56–1.84 | 0.968 |
| Malignancy | 3 (1.8) | 0 (0.0) | 0.269 | ||
| End-stage renal disease | 0 (0.0) | 0 (0.0) | |||
| End-stage liver disease | 4 (2.4) | 1 (0.8) | 0.35 | 0.04–3.13 | 0.406 |
| Human immunodeficiency virus infection | 2 (1.2) | 5 (4.1) | 3.62 | 0.69–18.98 | 0.13 |
| Injection drug use | 12 (7.1) | 13 (10.7) | 1.59 | 0.70–3.61 | 0.269 |
| Residence in a correctional facility | 13 (7.6) | 8 (6.6) | 0.86 | 0.34–2.13 | 0.737 |
| Active tobacco smoking | 64 (37.6) | 45 (37.2) | 0.98 | 0.61–1.59 | 0.937 |
| History of trauma on admission | 4 (2.4) | 9 (7.4) | 3.34 | 1.00–11.09 | 0.046a |
| History of MRSA colonization or infection within previous 1 yr | 17 (10.0) | 12 (9.9) | 0.99 | 0.46–2.16 | 0.981 |
| Abscess | 135 (79.4) | 102 (84.3) | 1.39 | 0.75–2.57 | 0.291 |
| Receipt of incision and drainage | 82 (48.2) | 77 (63.6) | 1.88 | 1.17–3.03 | 0.009a |
| Requirement for hospitalization for SSSI management | 9 (5.3) | 4 (3.3) | 0.61 | 0.18–2.03 | 0.568 |
| Median (range) treatment duration (days) | 10 (7-13) | 9 (6-12) | 0.5 | ||
| No. (%) of patients with clinical resolution | 127 (74.7) | 88 (72.7) | 0.90 | 0.53–1.53 | 0.705 |
a
P ≤ 0.05.